PSMC4 Inhibitors

Inhibitors of PSMC4 typically target the proteasome complex as a whole, particularly its 26S subunit, where PSMC4 is a component. These inhibitors are crucial in understanding and manipulating the ubiquitin-proteasome pathway, a key cellular mechanism for degrading and recycling proteins. Bortezomib (Velcade) and Carfilzomib (PR-171) are among the most well-known proteasome inhibitors. They work by binding to and inhibiting the proteasomal catalytic core, which indirectly impacts the function of PSMC4. MG-132 and Lactacystin are peptide-based inhibitors that also target the proteasome's catalytic activity, thereby affecting the function of PSMC4. Their mechanism of action involves the inhibition of the proteasomal degradation pathway, leading to the accumulation of ubiquitinated proteins.

Newer inhibitors like Oprozomib and Ixazomib have been developed to provide more options in targeting the proteasome, with potential benefits in terms of specificity. These compounds also indirectly affect PSMC4 by inhibiting the overall activity of the 26S proteasome. Marizomib, Delanzomib, and Salinosporamide A (NPI-0052) are potent inhibitors with mechanisms similar to Bortezomib. They bind irreversibly to the proteasome, leading to sustained inhibition of its activity, and consequently affecting PSMC4. Epoxomicin is a natural product that selectively and irreversibly inhibits the proteasome. Its unique mechanism of action has made it a valuable tool for studying proteasome function and the role of components like PSMC4.